| VVOS 0.1638 -16.43% | CLGN 0.3879 8.35% | PCG 13.3 0.23% | GPRO 0.8762 46.06% | AIM 0.2407 6.50% | NVDA 216.77 -1.82% | TSLL 9.6 -3.71% | CNH 11.81 -0.17% | RDHL 0.9 36.16% | NVD 4.07 3.56% | NU 14.425 -0.86% | BITO 10.475 -1.46% | COOT 0.5432 -8.37% | AAL 13.2 -1.71% | FNGR 0.223 -43.97% | INTC 86.97 -2.84% | SOAR 0.2151 -7.48% | NCRA 2.32 -18.02% | SPCX 141.73 -1.36% | TSLA 360.91 -1.91% | PATH 18.35 -1.61% | LGCL 0.0351 -9.77% | ABEV 2.87 0.35% | AEHL 6.49 83.33% | PFE 28.8 1.19% | AMZN 254.87 -1.89% | NIO 4.075 -3.89% | NOK 10.055 -0.84% | BAC 61.94 -0.61% | SNAP 5.55 2.21% | KEEL 3.04 -3.49% | IBIT 44.075 -1.33% | TQQQ 69.07 -3.96% | WETO 7.67 39.96% | BMNR 24.45 -3.44% | AAPL 317 0.05% | PURR 11.73 -4.24% | F 13.94 0.43% | WBUY 0.8 -11.11% | ROIV 34.63 -0.03% | IREN 36.11 -2.72% | CDE 19.79 -4.76% | SPY 761.97 -0.66% | IONQ 39.31 0.28% | T 26.15 1.00% | HYG 79.2 -0.21% | SOFI 17.53 -1.96% | TLT 81.895 -0.76% | SLB 60.1 4.83% | PLUG 2.11 -2.31%

Phreesia, Inc. (NYSE:PHR) Reports Strong Revenue Growth Despite EPS Miss

(NYSE:PHR) is a healthcare technology company that provides patient intake management solutions. It helps healthcare providers streamline their operations and improve patient experiences. The company competes with other healthcare technology firms like Cerner and Allscripts. On March 30, 2026, Phreesia reported earnings per share (EPS) of $0.02, which was below the estimated $0.06. However, the company generated revenue of approximately $127.1 million, slightly surpassing the estimated $126.8 million.

Despite the lower-than-expected EPS, Phreesia achieved several financial milestones for the fiscal year ending January 31, 2026. The company reported a positive GAAP net income of $2.3 million and exceeded $100 million in Adjusted EBITDA. Additionally, Phreesia generated $50 million in free cash flow, with net cash from operating activities reaching $78.8 million. These achievements reflect the company's strong financial performance and operational efficiency.

Phreesia's total revenue for the fiscal fourth quarter was $127.1 million, marking a 16% increase compared to the previous year. The average number of healthcare services clients (AHSCs) rose by 7% year-over-year to 4,658, while total revenue per AHSC increased by 8% to $27,279. This growth indicates the company's ability to expand its client base and increase revenue per client, contributing to its overall financial success.

Despite these positive developments, Phreesia's shares experienced a decline of 5.8%, closing at $10.98 on Friday. Mizuho analyst Steven Valiquette maintained an Outperform rating for Phreesia but adjusted the price target from $22 to $19 on March 24, 2026. The company's stock opened at $11.88 on Monday, showing a 0.9% increase. Phreesia's stock has experienced a 52-week low of $10.75 and a high of $32.76, reflecting its volatility in the market.

Phreesia's financial health is supported by a quick and current ratio of 2.44, with a debt-to-equity ratio of 0.01. The company's market capitalization stands at $716 million and a beta of 0.67. These metrics indicate that Phreesia has a strong liquidity position and low leverage, which can help it navigate market fluctuations and invest in future growth opportunities.

Published on: March 31, 2026